Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.1876 | 0.6066 | 1 |
Brugia malayi | phosphoinositide-dependent protein kinase I | 0.1911 | 0.6181 | 0.6181 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0698 | 0.222 | 0.222 |
Brugia malayi | thymidylate synthase | 0.0698 | 0.222 | 0.222 |
Echinococcus multilocularis | 3 phosphoinositide dependent protein kinase 1 | 0.1911 | 0.6181 | 0.6181 |
Loa Loa (eye worm) | AGC/PDK1 protein kinase | 0.1911 | 0.6181 | 0.6181 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0935 | 0.2995 | 0.2995 |
Brugia malayi | Protein kinase domain containing protein | 0.1911 | 0.6181 | 0.6181 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.1876 | 0.6066 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.0698 | 0.222 | 0.222 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase, putative | 0.0332 | 0.1025 | 0.169 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0332 | 0.1025 | 0.1659 |
Echinococcus granulosus | thymidylate synthase | 0.0698 | 0.222 | 0.222 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0935 | 0.2995 | 0.2995 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1876 | 0.6066 | 1 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0698 | 0.222 | 0.222 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.1876 | 0.6066 | 1 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.1876 | 0.6066 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1876 | 0.6066 | 1 |
Loa Loa (eye worm) | AGC/PDK1 protein kinase | 0.1911 | 0.6181 | 0.6181 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0698 | 0.222 | 0.222 |
Mycobacterium tuberculosis | Hypothetical protein | 0.0332 | 0.1025 | 0.1025 |
Brugia malayi | hypothetical protein | 0.0332 | 0.1025 | 0.1025 |
Trichomonas vaginalis | AGC family protein kinase | 0.1911 | 0.6181 | 1 |
Onchocerca volvulus | 0.0698 | 0.222 | 1 | |
Trichomonas vaginalis | AGC family protein kinase | 0.1911 | 0.6181 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1911 | 0.6181 | 0.6181 |
Mycobacterium ulcerans | thymidylate synthase | 0.0698 | 0.222 | 0.222 |
Echinococcus granulosus | 3-phosphoinositide-dependent protein kinase 1 | 0.1911 | 0.6181 | 0.6181 |
Trichomonas vaginalis | AGC family protein kinase | 0.1911 | 0.6181 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.0698 | 0.222 | 0.222 |
Entamoeba histolytica | protein kinase, putative | 0.1911 | 0.6181 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.